Form 10-Q OncoMed Pharmaceuticals For: Mar 31
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/2/2026
- Wall St futures rise ahead of jobs report as bond market steadies, oil slips
- U.S. economy adds fewer jobs than expected as unemployment rate ticks higher
- Nvidia returns as Morgan Stanley’s Top Pick on attractive valuation
- Citi says rate volatility without Fed repricing is concerning
- U.S. credit-reporting stocks fall as FHFA weighs two-bureau mortgage rule
- DataMeds AI's Corexa Pharmacy tops $1M in monthly revenue
- Equities rebound to close higher as surging Treasury yields recede
- onsemi cuts Synaptics deal price to $5.7B after rival bid
- Twilio, Vylor set to join S&P 500 as index reshuffles members
- Amazon and these four U.S. stocks are latest additions to Goldman’s flagship list
OncoMed Pharma (OMED) Misses Q1 EPS by 17c
May 5, 2016 5:20 PM EDTOncoMed Pharma (NASDAQ: OMED) reported Q1 EPS of ($0.90), $0.17 worse than the analyst estimate of ($0.73). Revenue for the quarter came in at $6.4 million versus the consensus estimate of $8.28 million.
For earnings history and earnings-related data on OncoMed Pharma (OMED) click here.
... More